

DAFTAR PUSTAKA

1. Lyon AR, Lopez-Fenandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *European Heart Journal*. 2022 ; 43 : 4229–4361
2. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining Cardiovascular Toxicities of Cancer Therapies : an International Cardio-Oncology Society (IC-OS) Consensus Statement. *European Heart Journal*. 2021 ; 00 : 1–23
3. Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, et al. Cardiovascular Toxicity Related to Cancer Treatment : A Pragmatic Approach to The American dan European Cardio-Oncology Guidelines. *J Am Heart Assoc*. 2020
4. Curigliano G, Cardinale D, Dent S, Crispiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatment : epidemiology, detection, and management. *CA CANCER J CLIN*. 2016 ; 66 : 309–325
5. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. *Heart*. 2018 ; 104 : 971–977
6. Grakova EV, Shilov SN, Kopeva KV, Berezikova EN, Popova AA, Neupokoeva MN, et al. Anthracycline-Induced cardiotoxicity: The role of endothelial dysfunction. *Cardiology*. 2021 ; 146 : 315–323
7. Faheri E, Acang N, Wahid I, Karani Y. Efek samping kemoterapi doksorubisin dosis menengah terhadap jantung pada pasien limfoma malignum non Hodgkin's [Tesis]. Padang. Fakultas Kedokteran Universitas Andalas ; 2008
8. Maifitriani, Sutandyo N, Andrajati R. Faktor yang mempengaruhi penurunan fraksi ejeksi ventrikel kiri pada pasien kanker yang mendapatkan kemoterapi doksorubisin di Rumah Sakit Kanker Dharmais. *Media Farmasi*. 2015 ; 12(2) : 233–246

9. Chang HM, Moudgil R, Scarabelli T, Okwuosa T, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management. *J Am Coll Cardiol.* 2017 ; 70(20) : 2536–2551
10. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA CANCER J CLIN.* 2021 ; 71 : 209–249
11. Setiyoahadi, B. 2009. Limfoma Non-Hodgkin. Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi V. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam ; 1251–1260
12. Bakta IM. 2007. Limfoma maligna. Hematologi klinik ringkas. Cetakan I. Jakarta: EGC ; p.192–219
13. Hoffbrand A.V. 2005. Limfoma maligna. Kapita Selekta Hematologi Edisi 4. Jakarta: EGC ; 185–198
14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2021 ; 00 : 1–128
15. Groenewegen A, Ruten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. *Eur J Heart Fail.* 2020 ; 22 : 1342–56
16. Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2000–2014. *NCHS Data Brief.* 2015 ; 231 : 1–8
17. Siswanto. Riset kesehatan dasar (Riskesdas) 2018. Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. 2018 ; 1 : 1–581
18. Takashio S, Takahama H, Nishikimi T, Hayashi T, Okatani CN, Matsuo A, et al. Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and the other natriuretic peptide forms. *BMJ.* 2019 ; 6 : 1–9
19. Krupicka J, Janota T, Hradec J. Natriuretic peptides in heart failure. *Cor Et Vasa.* 2013 ; 55 : 370–6
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 guideline for the management of heart failure. *JACC.* 2017 ; 70(96) : 777–803

21. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. *J Clin Oncol* 2019 ; 37 : 1946–1955
22. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al. Cardiovascular biomarkers in patients with cancer and their association with all cause mortality. *Heart*. 2015 ; 101 : 1874–1880
23. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginin (ADMA) in endothel dysfunction and cardiac disease. *Current Cardiology Reviews*. 2010 ; 6 : 82–90
24. Nemeth B, Ajtay Z, Hejjel L, Ferenci T, Abram Z, Muranyi E et al. The issue of plasma asymmetric dimethylarginine reference range-A systematic review and meta-analysis. *PLoS ONE*. 2017; 12(5):1–12
25. Krainer EK, Shah AM, Gupta DK, Santos A, Clagget B, Pieske B, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. *J Am Coll Cardiol*. 2014 ; 63(5) : 447–56
26. Ito H, Ishida M, Makino W, Goto Y, Ichikawa Y, Kitagawa K, et al. Cardiovascular magnetic resonance feature tracking for characterization of patients with HFpEF: correlation of global longitudinal strain with invasive diastolic functional indices. *J Cardiovasc Magn Reson*. 2020 ; 4(22) : 1–42
27. Rahimi AA, Hanif AM, Asir TR. Korelasi antara kadar n-terminal pro b-type natriuretic peptide serum dengan nilai global longitudinal strain pada heart failure with preserved ejection fraction [Tesis]. Padang. Fakultas Kedokteran Universitas Andalas; 2022
28. Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. *European Heart Journal*. 2016 ; 37 : 2768–2801
29. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. *Int J Mol Sci*. 2019 ; 20 : 1–16
30. Tanase DM, Radu S, Shurbaji SA, Baroi GL, Costea CF, Turliuc MD, et al. Natriuretic peptides in heart failure with preserved left ventricular ejection

- fraction: from molecular evidence to clinical implications. *Int J Mol Sci.* 2019 ; 20 : 1–23
31. Lee G, Ryan M. National laboratory book: laboratory testing for natriuretic peptides (NP) - BNP / NT-proBNP. *Nat Clin Prog Pathol.* 2019 ; 1 : 1–17
 32. Rogic D. NT-proBNP diagnostic significance and recommended clinical applications. *Signa Vitae.* 2015 ; 10(1) : 89–91
 33. Ibrahim NE, Januzzi JL. Established and emerging roles of biomarkers in heart failure. *Circ Res.* 2018 ; 123 : 614–29
 34. Voigt JU, Cvijic M. 2- and 3- dimensional myocardial strain in cardiac health and disease. *JACC.* 2019 ; 12(9) : 1849–63
 35. Yingchoncharoen T, Agarwal S, Popovic ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. *J Am Soc Echocardiogr.* 2013 ; 26 : 185–91
 36. Lang RM, Badano LP, Avi VM, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging. *J Am Soc Echocardiogr.* 2015 ; 28(1) : 1F–39
 37. Maia RJ, Brandao CS, Leite J, Parente GB, Pinheiro F, Araujo BT, et al. Global longitudinal strain predicts poor functional capacity in patients with systolic heart failure. *Arq Bras Cardiol.* 2019 ; 113(2) : 188–94
 38. Stokke TM, Hasselberg NE, Smedrud MK, Sarvari SI, Haugaa KH, Smiseth OA, et al. Assessing ventricular systolic function: comparison between ejection fraction and strain. *J Am Coll Cardiol.* 2017 ; 70(8) : 942–54
 39. Bshiebish HA, Musawi AH, Khudeir SA. Role of global longitudinal strain in assesment of left ventricular systolic function in patients with heart failure with preserved ejection fraction. *J Saudi Heart Assoc.* 2019 ; 31 : 100–5
 40. Lumens J, Tayal B, Walmsley J, Montero AD, Huntjens PR, Schwartzman D, et al. Differentiating electromechanical from non-electrical substrates of mechanical discoordination to identify responders to cardiac resynchronization therapy. *Circ Imaging.* 2015 ; 8 : 1–10

41. Park JJ, Mebazaa A, Hwang IC, Park JB, Park JH, Cho GY, et al. Phenotyping heart failure according to the longitudinal ejection fraction change: myocardial strain, predictors, and outcomes. *JAHA*. 2020 ; 9 : 1–17
42. DeVore A, McNulty S, Alenezi F, Ersboll M, Vader JM, Anstrom KJ, et al. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. *Eur J Heart Fail*. 2017 ; 19 : 893–900
43. Swain SM, Whaley FS and Ewer MS. Congestive heart failure in patient treated with doxorubicine a retrospective analysis of three trials. *CANCER*. 2003 ; 97(11) : 2869–2879
44. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN and Giordano SH. Congestive heart failure in older women treated with adjuvant chemotherapy for breast cancer. *J Clin Oncol*, 2007 ; 25(25) : 3808–3815
45. Finkelman BS, Putt M, Wang T, Wang L, Narayan H, Domchek S et al. Early changes in arginine-nitric oxide metabolites and subsequent cardiac dysfunction in breast cancer patients. *J Am Coll Cardiol*. 2017 ; 70(2) : 152–162
46. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/1970/2022 Tentang Perubahan atas Keputusan Menteri Kesehatan Nomor HK.01.07/Menkes/6485/2021 Tentang Formularium Nasional.
47. Airlangga MP, Romdoni R, Asharianti A. The effect of CHOP chemotherapy implementation toward reduced global longitudinal strain in non-Hodgkin lymphoma. *Indian Journal of Forensic Medicine and Toxicology*. 2020 ; 14(2) : 1353–1358
48. Gripp EDA, Olivera GE, Feijo LA, Garcia ML, Xavier SS, Sousa AS. Global longitudinal strain accuracy for cardiotoxicity prediction in a cohort of breast cancer patients during anthracycline and/or trastuzumab treatment. *Arq Bras Cardiol*. 2018 ; 110(2) : 140–150
49. Sahreni R, Acang N, Faheri E. Korelasi antara ekspresi phosphorylated AKT dengan kadar laktat dehidrogenase serum pada limfoma non hodgkin [Tesis]. Padang. Fakultas Kedokteran Universitas Andalas; 2018

50. SEER Cancer Stat Facts: Non-Hodgkin Lymphoma. National Cancer Institute. Bethesda, MD, <https://seer.cancer.gov/statfacts/html/nhl.html>
51. Wang B, Yu Y, Zhang Y, Hao X, Zhao H, Yang S et al. Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with R-CHOP regimen. *Echocardiography*. 2020 ; 00 : 1–8
52. Nakayama T, Oshima Y, Kusumoto S, Yamamoto J, Osaga S, Fujinami H et al. Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational study. *eJHaem*. 2020 ; 1 : 498–506
53. D'Elia N, Caselli S, Kosmala W, Lancellotti P, Morris D, Muraru D et al. Letters to the editor Normal global longitudinal strain an individual patient Meta-Analysis. *JACC: Cardiovascular Imaging*. 2020 ; 13(1) : 1–3
54. Jacob KR, Karpurmath SV, Nandennavar M, dan Angadi V. The correlation of doxorubicin related cardiotoxicity with B-type natriuretic peptide levels in south indian population. *Int J Med Res Rev*. 2019 ; 7(6) : 452–460
55. Chandra AP, Heri DH dan Wursito. Peningkatan NT-proBNP dan cTn-I serum pasien limfoma non hodgkin's yang menerima kemoterapi berbasis doksorubisin. *Jurnal Kedokteran Brawijaya*. 2016 ; 2(7) : 143–148
56. Muckiene G, Vaitiekus D, Zaliaduonyete D, Zabiela V, Verseckaite-costa R, Vaiciulienė D et al. Prognostic impact of global longitudinal strain and NT-proBNP on early development of cardiotoxicity in breast cancer patients treated with anthracycline-based chemotherapy. *Medicina*, 2023 ; 59(953) : 1–13
57. Dodos F, Halbsguth T. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline induced cardiotoxicity in adults. *Clin Res Cardiol*. 2008 ; 97 : 318–326
58. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. *Ann Oncol*. 2012 ; 23 : vii155–vii166

59. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. *Yonsei Med J.* 2010 ; 17 : 151–163
60. Chovanec JJ, Chovanec JS, Chovanec M, and Mego M. Levels of NT-proBNP in patients with cancer. *Oncology Letters.* 2023 ; 280(26) : 1–8
61. Sulaiman L, Hesham D, Hamid MA, Youseff. The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients. *The Egyptian Heart Journal.* 2021 ; 73(20) : 1–11
62. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P et al. N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?. *Clinical Chemistry.* 2005 ; 51(8)
63. Murtagh G, Januzzi JL, Scherrer-Crosbie M, Neilan TG, Dent S, Ho JE et al. Circulating Cardiovascular Biomarkers in Cancer Therapeutics-Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions. *J Am Heart Assoc.* 2023 ; 12e029574 : 1–16
64. Alexieva B, Sainova IV, Pavlova VG, Markova T, and Nikolova EB. Insight into mechanism of doxorubicin cardiotoxicity. *Journal of Physiology and Pharmacology.* 2014 ; 4(3) : 342–348
65. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. *Br J Cancer.* 2002 ; 86(11) : 1697
66. Bojan A, Torok-Vistai T, Parvu A. Review Article assesment and management of cardiotoxicity in hematologic malignancy. *Hindawi Disease Markers.* 2021 ; 6616265
67. Sawaya H, Sebag I. A., Plana J. C. et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. *The American Journal of Cardiology.* 2011 ; 107(9) : 1375–1380
68. Hinrich L, Mrotzek SM, Mincu R, Pohl J, Roll A, Michel L et al. Troponin and natriuretic peptide in cardio-oncology patients-data from the ECoR registry. *Frontiers in Pharmacology.* 2020 ; 7 (740) : 1–10

69. De Iuliis F, Salerno G, Taglieri L, De Biase L, Lanza R, Cardelli P et al. Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients. *Tumour Biol.* 2016 ; 37 : 3379–3387
70. Oral I, Brain natriuretic peptide as prognostic marker of two-year survival in patients with heart failure in a long-term dialysis programme. *Interventional Cardiology.* 2006 ; 3: 112-115
71. Kamai T, Tokura Y, Uematsu T, Sakamoto K, Suzuki I, Takei K, et al: Elevated serum levels of cardiovascular biomarkers are associated with progression of renal cancer. *Open Heart.* 2018 ; 5: e000666
72. Gimeno E, Gomez M, Gonzalez JR, Comin J, Alvarez-Larran, Sanchez- Gonzalez B, et al. NT-proBNP: A cardiac biomarker to assess prognosis in nonHodgkin Lymphoma. *Leukemia Research.* 2011 ; 35 : 715–720
73. Kamelia T, Waspadji S, Makmun LH, Effendi S, Ramli M. The changes of amino terminal pro B-type natriuretic peptide (NT-proBNP) concentration and left ventricular ejection fraction on doxorubicin chemotherapy patients. *Jurnal Penyakit Dalam Indonesia.* 2017 ; Vol 4 ; Iss 2, Article 6.

